Jafar Alavy Toussy

Jafar Alavy Toussy

Auto-generated profile, based on publicly available information

Jafar Alavy Toussy

Department of Infertility, Amir-AL-Momenin Hospital, Semnan University of Medical Sciences, Semnan, Iran

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SMShahrokh Mousavi
Shahrokh Mousavi
JTJafar Toussy
Jafar Toussy
SYSiamak Yaghmaie
Siamak Yaghmaie
MZMehrdad Zahmatkesh
Mehrdad Zahmatkesh
Azithromycin in one week quadruple therapy for H pylori eradication in Iran

1 November 2007
Verified
Journal Article
Closed access
SMShahrokh Mousavi
Shahrokh Mousavi
JTJafar Alavy Toussy
Jafar Alavy Toussy
MZMehrdad Zahmatkesh
Mehrdad Zahmatkesh

1 March 2007 in Saudi Medical Journal
Verified
Journal Article
Closed access
JMJamileh Moghimi
Jamileh Moghimi
JTJafar Toussy
Jafar Toussy
MBMehdi Babaei
Mehdi Babaei
SMShahrokh Mousavi
Shahrokh Mousavi
MTMohamadreza Tamadon
Mohamadreza Tamadon
MKMasomeh Karamai
Masomeh Karamai

1 January 2012
Verified
Journal Article
Open access
AAAzam Azargoon
Azam Azargoon
JTJafar Alavy Toussy
Jafar Alavy Toussy
FDFakhry Fakhr Darbanan
Fakhry Fakhr Darbanan
Background: Clomiphen citrate (CC) is the first line therapy for women with infertility and poly cystic ovary syndrome( PCOS). However, 20-25% of women are resistant to CC and do not ovulate.

1 March 2013
Verified
Journal Article
Open access
AAAzam Azargoon
Azam Azargoon
MBMarjan Bahrami
Marjan Bahrami
JTJafar Alavy Toussy
Jafar Alavy Toussy
Background: Different protocols are used for controlled ovarian hyper stimulation (COH), but the optimal method has not yet been determined. Objective: The aim of this study was to compare the outcome of controlled ovarian stimulation (COS) using clomiphen citrate (CC) plus HMG versus CC plus rFSH in intra uterine insemination cycles (IUI). Materials and Methods: 144 women with unexplained or male factor infertility undergoing IUI cycles were randomized (72 patients in CC plus rFSH group and 72 patients in CC plus HMG group) and included in this single blind study from October 2006 to June 2010. The primary outcomes were clinical and ongoing pregnancy rates. The number of dominant follicles, mean of follicular size, endometrial thickness on the day of HCG administration, total dose of gonadotropins and duration of stimulation with gonadotropins were secondary outcomes. Results: Clinical and ongoing pregnancy rates were not significantly different in the two groups. There was a significant higher multiple pregnancy rate in CC plus rFSH group (33.3%) versus CC plus HMG group (12.5%; p<0.005). There were no statistically significant differences in the secondary outcomes between the two groups. Conclusion: According to our results it seems that CC plus HMG is a more suitable and cost-effective regimen than CC plus rFSH in IUI cycles in patients with unexplained or male factor infertility.